AstraZeneca has just provided open access to the clinical trial data for its drug Crestor (rosuvastatin calcium). I won't blog all future examples of OA to drug trial data, but it's worth blogging the early examples to prove that we're entering a new world of access. See the company press release. (PS: The AstraZeneca release is commendable and I'm commending it. However, it does not fulfill the conditions of the public statement from the International Committee of Medical Journal Editors because the data are available only on the company web site and not from a central database managed by a non-profit organization.)
Posted by
Peter Suber at 10/08/2004 07:48:00 AM.
The open access movement:
Putting peer-reviewed scientific and scholarly literature
on the internet. Making it available free of charge and
free of most copyright and licensing restrictions.
Removing the barriers to serious research.
